Vigilant Biosciences' first test to aid in diagnosis of Oral Cancer

Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has CE Marked its OncAlert Oral Cancer CD44/Total Protein LAB Test. CE Marking allows Vigilant Biosciences to market the product in the 28 countries of the European Union (EU) as well as Norway, Iceland, Liechtenstein and Switzerland.

Vigilant Biosciences' OncAlert LAB Assay is a noninvasive, accurate and cost-effective, quantitative tool for clinicians involved in the diagnosis and treatment of oral cancer. It is the first and only test to detect a tumor-initiating stem cell biomarker for head and neck cancer. The test measures soluble CD44 and total protein levels – specific protein markers known to indicate early stage cancers – in an oral rinse, to serve as an aid in diagnosis of oral cancer, along with other clinical factors.

As previously announced, Vigilant Biosciences has multiple distribution agreements secured across the EU and expects to begin shipping the product during the first quarter of 2016.